Updated Health Economics Simulation Model of the Lifetime Progression of Multiple Sclerosis in an Australian Setting [0.03%]
澳大利亚多发性硬化症终生进展的健康经济模拟模型更新研究
Andrew J Palmer,Ting Zhao,Glen Henson et al.
Andrew J Palmer et al.
Background: Multiple sclerosis (MS) is a progressive disease leading to increasing disability. Our previous simulation model estimated lifetime impacts of MS on quality of life and associated economic costs but was limite...
Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis [0.03%]
绝经后骨质疏松症生物仿制药denosumab与双磷酸盐的性价比研究
Jeanine Flanigan,Sarah Kane,Fatemeh Mirzayeh Fashami et al.
Jeanine Flanigan et al.
Background/objectives: Postmenopausal osteoporosis (PMO) is a major public health and economic burden in the USA. The objective of this study was to evaluate the cost-effectiveness of biosimilar denosumab compared with al...
Exploring the Sensitivity of Utilities Predicted by the EQ-5D, SF-6D, HUI3, 15D, AQoL-4D, and AQoL-8D Multi-Attribute Utility Instruments to SF-36 Dimensions [0.03%]
探索由EQ-5D，SF-6D，HUI3，15D，AQoL-4D和AQoL-8D多属性效用仪器预测的效用对SF-36维度的敏感性
Josephine N A Tetteh,Michael Schlander
Josephine N A Tetteh
Background: Multi-attribute utility instruments (MAUIs) are commonly used in health economics to measure health-related quality of life (HRQoL), yet their sensitivity to different health domains varies. This study examine...
Trial-Based Economic Evaluations Conducted alongside Studies Embedded in Australian Healthcare Services and Programs: A Scoping Review [0.03%]
基于澳大利亚医疗卫生服务体系和项目的试验型经济评价：一项综述研究
Belinda Wang,Catherine Sherrington,Luiza R Pivotto et al.
Belinda Wang et al.
Objectives: The objective of this study was to map the literature and provide an overview of economic evaluations (EEs) conducted alongside studies embedded in Australian healthcare services or programs by: (1) providing ...
Health Utilities Associated with Pneumococcal Diseases in Children and Adults: A Targeted Literature Review and Meta-analysis [0.03%]
肺炎球菌病在儿童和成人中的健康效用损失：系统文献回顾及Meta分析
Min Huang,Hela Romdhani,Yan Song et al.
Min Huang et al.
Background: Pneumococcal disease and post-meningitis sequelae (PMS) impact health-related quality of life (HRQoL). However, health utility estimates for these conditions vary considerably in the literature, which may affe...
Correction: Incremental Disease Burden (Healthcare Costs and Resources) of Duchenne Muscular Dystrophy in the US: A Matched Cohort Analysis [0.03%]
对杜氏肌营养不良症在美国的增量疾病负担（医疗费用和资源）进行校正：匹配队列分析
Mena Scavina,Nate Posner,Patricia Dorling et al.
Mena Scavina et al.
Published Erratum
PharmacoEconomics - open. 2026 Mar 31. DOI:10.1007/s41669-026-00646-x 2026
Prevalence and Healthcare Costs of Metabolic Disorders Among Individuals with Schizophrenia Following Initiation of Oral Antipsychotic Therapy [0.03%]
口服抗精神病药物治疗后精神分裂症患者代谢障碍的患病率和医疗费用
Joseph Tkacz,Alejandro Cajigal,Matthew Sidovar et al.
Joseph Tkacz et al.
Background/objective: Metabolic disorders are prevalent among the schizophrenia population due to relatively poor access to healthcare, lifestyle factors, genetics, and metabolic side effects associated with antipsychotic...
Cost-Effectiveness of Follitropin Delta Compared with Follitropins Alfa and Beta in Controlled Ovarian Stimulation for Assisted Reproductive Technologies (ART) in France [0.03%]
法国辅助生殖技术控制卵巢刺激中 Follicrin delta 与 Follicrin alpha 和 beta 的成本效益比较
Samir Hamamah,Jeremy Carette,Henri Leleu et al.
Samir Hamamah et al.
Background: Follitropin delta, using a personalized dosing regimen, is an effective treatment option for women undergoing controlled ovarian stimulation (COS) for in vitro fertilization (IVF)/intracytoplasmic sperm inject...
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned? [0.03%]
西班牙中重度克罗恩病序贯治疗策略的成本效益分析：生物类似物乌司奴单抗应处于什么位置？
Iago Rodríguez-Lago,José Ignacio Peinado-Fabregat,Marcelo Guigini et al.
Iago Rodríguez-Lago et al.
Background/objective: Crohn's disease is associated with a high economic burden for the Spanish National Healthcare System, driven by pharmacological expenses. Following the recent incorporation of ustekinumab biosimilars...
Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States [0.03%]
关于在美国治疗湿性年龄相关性黄斑变性(FAΜD)的Faricimab与Aflibercept成本效用分析
Ahmead Baljoon,Vakaramoko Diaby,Sandra Suther et al.
Ahmead Baljoon et al.
Background/objective: Neovascular age-related macular degeneration (nAMD) imposes a substantial clinical and economic burden in the United States (US). Faricimab offers the potential for longer dosing intervals than aflib...